CVS Surpassed By MetLife, Analyst Says

 

An extensive study of the recommendations from analysts at all major brokerages found that MetLife Inc. has overtaken the number 52 spot, which was once held by CVS Caremark Corporation (NYSE:CVS), Forbes reports.

According to the news source, ETF Channel combined the data by tallying and averaging the analysts remarks, then ranked those underlying components according to the averages. Although investors typically see different patterns in different data, popular analyst picks still emerge, as many individual minds often can create a single bullish idea.

However, if that stock falls at all, it would be seen as negative, and could further impact the stock. According to ETF Channel data, MetLife and CVS together make up 5.03 percent of the Dynamic Market Portfolio ETF, which today is trading lower at about 0.1 percent.

This loss to Metlife may have been the reason for a surge in insider trades among CVS officials recently. According to insider trading reports field with the SEC, Larry Merlo exercised his market option on July 2 for 161,359 shares valued at  $30.03 each, then sold those shares for $46.96 for a profit of 2.73 million.

Do you think you should start selling CVS stock, too?

Read Full Insider Report For:   CVS  |

Related News:

Disclaimer

InsidersLab.com focuses on tracking and monitoring insider trading activities in the US stocks market. "Insider Trading" means trading activities created by company directors, senior officers, individual substantial shareholders, and institutional shareholders. InsidersLab.com does not represent, warrant, nor endorse the accuracy, reliability, completeness or timeliness of any of the information, content, views, opinions, recommendations or advertisements (collectively, the "Materials") contained on, distributed through, or linked, downloaded or accessed from any of the services contained on the website (the "Service"), nor the quality of any products, information or other materials displayed, purchased, or obtained by you as a result of an advertisement or any other information or offer in or in connection with the Service (the "Products"). InsidersLab.com collects insider trading information from different public sources such as newspapers, financial information websites, and government statistics publications. You hereby acknowledge that any reliance upon any Materials shall be at your sole risk. In particular, none of the Materials is provided on the InsidersLab.com website or emails with a view to inviting, inducing or encouraging any person to make any kind of investment decision. Securities or other investments referred to in the Materials may not be suitable for you and you should not make any kind of investment decision in relation to them without first obtaining independent investment advice from a person authorized to give it.